We are live on ! Find out more
MESO

Mesoblast

72 hedge funds and large institutions have $53.3M invested in Mesoblast in 2026 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 20 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

908% more call options, than puts

Call options by funds: $34M | Put options by funds: $3.38M

50% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 6

20% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 20

5% more capital invested

Capital invested by funds: $50.5M → $53.3M (+$2.76M)

4% more funds holding

Funds holding: 6972 (+3)

0.44% more ownership

Funds ownership: 2.55%2.99% (+0.44%)

Holders
72
Holders Change
+3
Holders Change %
+4.35%
% of All Funds
0.87%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
24
Reduced
20
Closed
6
Calls
$34M
Puts
$3.38M
Net Calls
+$30.7M
Net Calls Change
+$8.73M

MESO Hedge Fund Activity: Q2 2026 in Review

72 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Mesoblast (MESO) for Q2 2026, worth a combined $53.3M — up 5.5% from $50.5M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new MESO positions and 6 closed out — a net gain of 3 holders — while 24 added to existing stakes and 20 trimmed.

The largest buyer was BNP Paribas Asset Management, opening a new position worth an estimated $3.86M. The largest seller was Citadel Advisors, exiting entirely with an estimated $1.28M sold.

  • 72 institutional investors held Mesoblast (MESO) as of Q2 2026, up from 69 in Q1 2026.
  • Funds reported $53.3M of Mesoblast stock for Q2 2026, up 5.5% quarter-over-quarter.
  • 9 funds opened new Mesoblast positions in Q2 2026 and 6 closed out, a net change of +3 holders.
  • The largest Mesoblast buyer in Q2 2026 was BNP Paribas Asset Management, an estimated $3.86M added.
  • The largest Mesoblast seller in Q2 2026 was Citadel Advisors, an estimated $1.28M sold.

Based on aggregated 13F filings for Q2 2026.